Physician

Dianna L Shipley, MD

According to 2025 Medicare claims, Dianna Shipley, MD (NPI: 1700810371) practices medical oncology in the Nashville-Davidson--Murfreesboro--Franklin, TN market, with the plurality of this provider's patient population coming from Sumner, TN. This provider's primary affiliated billing organization is TENNESSEE ONCOLOGY PLLC (NPI: 1811955917; TIN: 621647259) and primary practice location at 37066-8466.

Shipley's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 807 traditional Medicare patients, billed 206,632 HCPCS/CPT codes, and received $3,206,917 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,909 prescription claims across 383 beneficiaries totaling $5,761,011 in drug costs, led by Ibrance (Palbociclib). DME data shows 33 claims. Open Payments data shows 82 records totaling $1,978. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,375,239 and ending at $3,206,917. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,325,343 to $5,761,011. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,475 to $1,089.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	789	342,593	$2,375,239
2016	796	347,135	$2,518,106
2017	827	346,601	$2,604,841
2018	889	419,321	$3,770,034
2019	954	495,128	$4,206,442
2020	912	436,720	$3,766,427
2021	930	320,509	$2,711,451
2022	812	288,839	$2,820,071
2023	779	206,744	$2,277,673
2024	807	206,632	$3,206,917

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	338	2,038	$1,325,343
2016	344	2,086	$1,354,516
2017	359	1,877	$1,538,409
2018	382	1,978	$2,601,391
2019	431	2,412	$2,797,503
2020	439	2,337	$3,604,929
2021	426	2,073	$4,777,783
2022	403	2,027	$5,787,559
2023	377	1,909	$5,242,330
2024	383	1,909	$5,761,011

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	73	356	$52,795
2016	N/R	225	$40,124
2017	N/R	106	$18,340
2018	N/R	89	$12,383
2019	44	204	$19,041
2020	30	147	$11,033
2021	N/R	126	$7,063
2022	11	63	$1,905
2023	N/R	74	$17,403
2024	N/R	33	$808

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	349	478	$82
80053	Blood test, comprehensive group of blood chemicals	619	1,779	$10
36415	Insertion of needle into vein for collection of blood sample	678	1,976	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	642	2,243	$8
83540	Iron level	231	437	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	68	1,904	$990,476
Revlimid	Lenalidomide	64	1,700	$932,595
Jakafi	Ruxolitinib Phosphate	42	1,260	$611,308
Verzenio	Abemaciclib	27	756	$394,603
Brukinsa	Zanubrutinib	26	780	$368,246

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	18	$545
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	82	$1,978	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dianna L. Shipley, MD?

Tedicare shows public-source Medicare data for Dianna L. Shipley, MD (NPI 1700810371), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dianna L. Shipley, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Dianna L. Shipley, MD?

Dianna L. Shipley, MD is linked to TENNESSEE ONCOLOGY PLLC (billing NPI 1811955917) in the available physician profile data.

Does Dianna L. Shipley, MD have Open Payments data?

Dianna L. Shipley, MD has 82 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.